EpCAM anticorps (Extracellular)

N° du produit ABIN4949641

L’anticorps anti-EpCAM Monoclonal Souris est utilisé pour la détection de EpCAM dans des échantillons de Humain, Cat, Chien et Cobaye. Il a été validé pour WB, IF, ELISA et IHC (p).

Aperçu rapide pour EpCAM anticorps (Extracellular) (ABIN4949641)

Antigène: EpCAM (EPCAM) (Epithelial Cell Adhesion Molecule (EPCAM))

Reactivité: Humain, Cat, Chien, Cobaye

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp EpCAM est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: EGP40-1384

Détail du produit anti-EpCAM anticorps

Épitope: AA 100-224, Extracellular

Fonction: EpCAM Antibody / Extracellular domain (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogène: A human partial recombinant protein corresponding to amino acids 100-224 (extracellular domain) was used as the immunogen for the EpCAM antibody.

Isotype: IgG

Information d'application

Indications d'application: Titering of the EpCAM antibody may be required for optimal performance.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the EpCAM antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur EpCAM

Antigène: EpCAM (EPCAM) (Epithelial Cell Adhesion Molecule (EPCAM))

Autre désignation: EpCAM

Sujet: EpCAM (Epithelial Cell Adhesion Molecule), also known as CD326, plays a crucial role in various cellular processes and has been linked to the development and progression of cancer. EpCAM is a transmembrane glycoprotein that is expressed in high levels on the surface of epithelial cells. In cancer cells, the expression of EpCAM is often upregulated, leading to increased cell proliferation, invasion, and metastasis. Studies have shown that high levels of EpCAM are associated with poor prognosis in various types of cancer, including breast, colon, and lung cancer. The overexpression of EpCAM in cancer cells makes it an attractive target for diagnostic and therapeutic purposes. Researchers are exploring the use of EpCAM as a biomarker for early cancer detection through blood tests and imaging techniques. In addition, EpCAM-targeted therapies, such as monoclonal antibodies and immunotherapies, are being developed to specifically target and kill cancer cells that overexpress EpCAM.

UniProt: P16422